TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
←
▶ 3:07 · $OPENAI · $ARK-INVEST · The AI Bubble Narrative Is "Flat Wrong" | ARK Invest’s Brett Winton
episode briefing
The Information

The AI Bubble Narrative Is "Flat Wrong" | ARK Invest’s Brett Winton

2025-11-11 · 6 company · 0 thematic
sentiment
5 bull0 bear1 neu
quote
“Well, certainly in our venture fund, we have um a lot of exposure to AI. Uh we have in in our top holdings, we have OpenAI, XAI, and Anthropic. So we think that the foundation model platforms are going to be remarkably valuable on the orde…”
—unknown
now playing · $OPENAI · $ARK-INVEST
$OPENAIbullish· mediumunknown
OpenAI foundation models seen worth $15‑20tn by 2030
ARK Invest expects foundation model platforms like OpenAI to be worth $15‑20 trillion by 2030, arguing current revenue projections undervalue their pricing power from AI‑driven pr…
$ARK-INVESTbullish· mediumunknown
ARK Invest’s venture fund sees $15‑20tn foundation model opportunity
ARK Invest’s venture fund holds OpenAI, XAI and Anthropic and expects foundation model platforms to be worth $15‑20 trillion by 2030, driving its AI‑focused investment strategy.
$TSLA···bullish· highunknown
Tesla seen as largest AI project with robo‑taxi cash flow boom
ARK Invest views Tesla as the world's largest AI initiative, expecting its robo‑taxi rollout to generate hundreds of billions in cash flow and pave the way for humanoid robots, dr…
$AMD···bullish· mediumunknown
AMD gaining traction in AI chips with larger memory advantage
ARK Invest sees AMD’s broad AI chip offering gaining traction because its higher memory attachment gives it an edge in the growing AI data center market.
$NVDA···neutral· mediumunknown
Nvidia still interesting despite falling share in $3‑4tn AI capex
ARK Invest expects $3‑4 trillion of AI data center spending by 2030; while Nvidia’s market share may decline, the absolute opportunity remains large enough to justify an interesti…
$NTLA···bullish· mediumunknown
Intellia’s hereditary angioedema cure seen as $20‑30bn opportunity
ARK Invest believes Intellia’s prospective cure for hereditary angioedema could command multi‑million‑dollar pricing, implying a $20‑30 billion market despite the stock’s recent d…